rs762292600
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis of TCGA breast cancer data revealed that the mRNA expression, total protein levels, and phosphorylation of various RTKs are decreased in human tumors harboring AKT1(E17K).
|
27004402 |
2016 |
rs762292600
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
AKT1 mutations (E17K) have been found in 1.4-8% of breast cancer patients.
|
29086897 |
2018 |
rs762292600
|
|
Carcinogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
|
27004402 |
2016 |
rs762292600
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
AKT1 mutations (E17K) have been found in 1.4-8% of breast cancer patients.
|
29086897 |
2018 |
rs762292600
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
Analysis of TCGA breast cancer data revealed that the mRNA expression, total protein levels, and phosphorylation of various RTKs are decreased in human tumors harboring AKT1(E17K).
|
27004402 |
2016 |
rs762292600
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Conclusion This study provides the first clinical data that AKT1 E17K is a therapeutic target in human cancer.
|
28489509 |
2017 |
rs762292600
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively.
|
28489509 |
2017 |
rs762292600
|
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Conclusion This study provides the first clinical data that AKT1 E17K is a therapeutic target in human cancer.
|
28489509 |
2017 |
rs762292600
|
|
Solid Neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively.
|
28489509 |
2017 |